rolipram has been researched along with Fatigue Syndrome, Chronic in 1 studies
Fatigue Syndrome, Chronic: A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Staines, DR | 1 |
1 other study available for rolipram and Fatigue Syndrome, Chronic
| Article | Year |
|---|---|
Phosphodiesterase inhibitors may be indicated in the treatment of postulated vasoactive neuropeptide autoimmune fatigue-related disorders.
Topics: Autoimmune Diseases; Cyclic AMP; Fatigue Syndrome, Chronic; Humans; Imipramine; Neuropeptides; Phosp | 2006 |